Global CRDMO Syngene offers end-to-end services across small molecules and biologics, all delivered from one campus. This allows us to manage projects centrally, unhindered by logistical/shipping delays or dependencies on third-party deliverables. For you, it translates to increased efficiency and faster access to patients. Our development lifecycle capabilities span process R&D, formulation development, analytical development, clinical development, and API commercial manufacturing (70,000L capacity). We have an installed biologics drug substance manufacturing capacity of 28,000L. We also offer a commercial-scale, high-speed, sterile fill-finish facility for small molecules and biologics. With a 30-year history in discovery, development, and manufacturing, we have worked with 1000+ companies and are the preferred partner to 400+ global organizations. We are also co-authors of 400+ customer patents. Our facilities are US FDA, EMA, and PMDA approved; GLP, GMP, ISO certified; AAALAC, ANVISA accredited.